{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:51:10Z","timestamp":1791521470505,"version":"4.3.4"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2024ZD0531300"],"award-info":[{"award-number":["2024ZD0531300"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014895","name":"Southwest Medical University","doi-asserted-by":"publisher","award":["2025LCYXZX42"],"award-info":[{"award-number":["2025LCYXZX42"]}],"id":[{"id":"10.13039\/501100014895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2025ZNSFSC1622"],"award-info":[{"award-number":["2025ZNSFSC1622"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300911"],"award-info":[{"award-number":["82300911"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470854"],"award-info":[{"award-number":["82470854"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20286"],"award-info":[{"award-number":["U22A20286"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.metabol.2026.156767","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T14:46:05Z","timestamp":1788705965000},"page":"156767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pan-PPAR agonists: Emerging therapeutic strategies for metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1016","volume":"184","author":[{"given":"Man","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-hao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-juan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-zhen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-yuan","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-zhe","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2026.156767_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1669478","article-title":"Metabolic dysfunction associated fatty liver disease and type 2 diabetes: pathophysiological links, epidemiological trends, and clinical implications","volume":"16","author":"Mohiuddin M","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2026.156767_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2026.156575","article-title":"Burden of metabolic diseases, 1990-2023, with forecasts to 2030 for the Asia-Pacific region","volume":"179","author":"Zhang","year":"2026","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.metabol.2026.156767_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"issue":"11","key":"10.1016\/j.metabol.2026.156767_bb0020","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00125-024-06196-3","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary","volume":"67","year":"2024","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.metabol.2026.156767_bb0025","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S2468-1253(25)00260-2","article-title":"Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis","volume":"11","author":"Li","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.metabol.2026.156767_bb0030","doi-asserted-by":"crossref","first-page":"C1637","DOI":"10.1152\/ajpcell.00951.2024","article-title":"Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease","volume":"328","author":"Kuchay M","year":"2025","journal-title":"Am J Physiol Cell Physiol"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0035","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jceh.2019.06.004","article-title":"Peroxisome proliferator-activated receptors and their agonists in nonalcoholic fatty liver disease","volume":"9","author":"Choudhary","year":"2019","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2026.156767_bb0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2026.156767_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol Res"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0050","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2026.156767_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol Metab"},{"issue":"5","key":"10.1016\/j.metabol.2026.156767_bb0060","doi-asserted-by":"crossref","first-page":"964","DOI":"10.4093\/dmj.2025.0644","article-title":"Hepatic insulin resistance and steatosis in metabolic dysfunction-associated steatotic liver disease: new insights into mechanisms and clinical implications","volume":"49","author":"Truong","year":"2025","journal-title":"Diabetes Metab J"},{"issue":"2","key":"10.1016\/j.metabol.2026.156767_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2024.100018","article-title":"Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: current and emerging therapeutic options","volume":"77","author":"Zhang","year":"2025","journal-title":"Pharmacol Rev"},{"issue":"12","key":"10.1016\/j.metabol.2026.156767_bb0070","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.ajpath.2023.08.007","article-title":"The role of endoplasmic reticulum in lipotoxicity during metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis","volume":"193","author":"Venkatesan","year":"2023","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.metabol.2026.156767_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/cells11020288","article-title":"Role of mitochondrial cytochrome P450 2E1 in healthy and diseased liver","volume":"11","author":"Massart","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.metabol.2026.156767_bb0080","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11739-023-03374-w","article-title":"Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review","volume":"19","author":"Di Vincenzo","year":"2024","journal-title":"Intern Emerg Med"},{"issue":"1","key":"10.1016\/j.metabol.2026.156767_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines14010151","article-title":"The role of Kupffer cells and liver macrophages in the pathogenesis of metabolic dysfunction-associated steatotic liver disease","volume":"14","author":"Tsomidis","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.metabol.2026.156767_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2026.156652","article-title":"Gut-liver metabolic and enterohormonal remodeling drives progression from metabolic dysfunction-associated steatotic liver disease to steatohepatitis","volume":"181","author":"Rivas","year":"2026","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156767_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.prmcm.2025.100743","article-title":"Modulatory role of traditional chinese medicine in gut\u2013liver and adipose\u2013liver axis dysfunction in MASLD","volume":"18","author":"Tanwar","year":"2026","journal-title":"Pharmacol Res - Mod Chin Med"},{"issue":"8","key":"10.1016\/j.metabol.2026.156767_bb0100","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26062394","article-title":"A comprehensive review of metabolic dysfunction-associated steatotic liver disease: its mechanistic development focusing on methylglyoxal and counterbalancing treatment strategies","volume":"26","author":"Berdowska","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"6294","key":"10.1016\/j.metabol.2026.156767_bb0110","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators","volume":"347","author":"Issemann","year":"1990","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.metabol.2026.156767_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112367","article-title":"The role of PPARs in disease","volume":"9","author":"Wagner","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.metabol.2026.156767_bb0120","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.metabol.2026.156767_bb0125","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jhep.2023.07.004","article-title":"Treating NASH by targeting peroxisome proliferator-activated receptors","volume":"79","author":"Staels","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2026.156767_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108391","article-title":"PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: pathogenesis and therapeutic targets","volume":"245","author":"Chen","year":"2023","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.metabol.2026.156767_bb0135","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPAR\u03b1 in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.metabol.2026.156767_bb0140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41423-025-01265-y","article-title":"Fueling defense: PPAR\u03b1 enhances macrophage inflammatory responses","volume":"22","author":"Hoeksema","year":"2025","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"10.1016\/j.metabol.2026.156767_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26031051","article-title":"Overexpression of apolipoprotein A-I alleviates insulin resistance in MASLD mice through the PPAR\u03b1 pathway","volume":"26","author":"Wang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2026.156767_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.157440","article-title":"PPAR\u03b1 activation attenuates neobavaisoflavone-induced hepatotoxicity by modulating metabolic disorder and oxidative stress","volume":"148","author":"Zhao","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.metabol.2026.156767_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155720","article-title":"The ubiquitin-like modifier FAT10 is induced in MASLD and impairs the lipid-regulatory activity of PPAR\u03b1","volume":"151","author":"Clavreul","year":"2024","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.metabol.2026.156767_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/biom13020252","article-title":"Suppressing hepatic UGT1A1 increases plasma bilirubin, lowers plasma Urobilin, reorganizes kinase signaling pathways and lipid species and improves fatty liver disease","volume":"13","author":"Bates","year":"2023","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0165","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1021\/acsnano.3c06107","article-title":"Antioxidative hyaluronic acid-bilirubin nanomedicine targeting activated hepatic stellate cells for anti-hepatic-fibrosis therapy","volume":"18","author":"Shinn","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.metabol.2026.156767_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123576","article-title":"Oral delivery of chitosan-bilirubin nanoparticles alleviates hepatic inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis","volume":"325","author":"Rahman","year":"2026","journal-title":"Biomaterials"},{"key":"10.1016\/j.metabol.2026.156767_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156128","article-title":"PPARalpha-ERRalpha crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression","volume":"164","author":"Antwi","year":"2025","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.metabol.2026.156767_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030913","article-title":"PPAR\u03b2\/\u03b4: a key therapeutic target in metabolic disorders","volume":"19","author":"Palomer","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.metabol.2026.156767_bb0185","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.14218\/JCTH.2023.00334","article-title":"An overview of the role of peroxisome proliferator-activated receptors in liver diseases","volume":"11","author":"Changizi","year":"2023","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0190","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cmet.2008.04.003","article-title":"Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance","volume":"7","author":"Odegaard","year":"2008","journal-title":"Cell Metab"},{"issue":"11","key":"10.1016\/j.metabol.2026.156767_bb0195","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1111\/febs.15877","article-title":"Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease","volume":"289","author":"Thibaut","year":"2022","journal-title":"FEBS J"},{"key":"10.1016\/j.metabol.2026.156767_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117303","article-title":"PPAR\u03b2\/\u03b4 attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells","volume":"179","author":"zhang m","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"10.1016\/j.metabol.2026.156767_bb0205","article-title":"The gut\u2013liver axis in liver disease: molecular mechanisms and therapeutic targets","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm (2020)"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0210","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1083\/jcb.200809028","article-title":"Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta\/delta is essential for skin homeostasis and wound healing","volume":"184","author":"Chong","year":"2009","journal-title":"J Cell Biol"},{"issue":"2","key":"10.1016\/j.metabol.2026.156767_bb0215","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/toxsci\/kfn142","article-title":"Ligand activation of peroxisome proliferator-activated receptor beta\/delta (PPARbeta\/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression","volume":"105","author":"Shan","year":"2008","journal-title":"Toxicol Sci"},{"issue":"2","key":"10.1016\/j.metabol.2026.156767_bb0220","doi-asserted-by":"crossref","first-page":"G120","DOI":"10.1152\/ajpgi.00158.2023","article-title":"Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis","volume":"326","author":"Choi","year":"2024","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.metabol.2026.156767_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2026.108144","article-title":"Mechanistic rationale of seladelpar\u2019s clinical efficacy through the selective PPAR-delta activation in primary biliary cholangitis","volume":"225","author":"Gerussi","year":"2026","journal-title":"Pharmacol Res"},{"issue":"10","key":"10.1016\/j.metabol.2026.156767_bb0230","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.metabol.2026.156767_bb0235","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.metabol.2026.156767_bb0240","article-title":"Metabolic reprogramming through polyphenol networks: a systems approach to metabolic inflammation and insulin resistance","volume":"13","author":"Shimu S","year":"2025","journal-title":"Med Sci (Basel)"},{"issue":"4","key":"10.1016\/j.metabol.2026.156767_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040535","article-title":"Insulin sensitization by PPARgamma and GLUT-4 overexpression\/translocation mediates the antidiabetic effect of Plantago australis","volume":"16","author":"Estrada-Soto","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/j.metabol.2026.156767_bb0250","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cell.2011.11.062","article-title":"Fibroblast growth factor-21 regulates PPAR\u03b3 activity and the antidiabetic actions of thiazolidinediones","volume":"148","author":"Dutchak","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.metabol.2026.156767_bb0255","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-2275(20)30159-0","article-title":"PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism","volume":"43","author":"Walczak","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2026.156767_bb0260","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.2147\/DDDT.S524893","article-title":"Therapeutic targeting of PPAR\u03b3 in nonalcoholic fatty liver disease: efficacy, safety, and drug development","volume":"19","author":"Zhou","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.metabol.2026.156767_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1620585","article-title":"Inflammation: a key mechanism connecting metabolic-associated steatotic liver disease and systemic arterial hypertension","volume":"16","author":"Solleiro-Villavicencio","year":"2025","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.metabol.2026.156767_bb0270","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/s41423-025-01307-5","article-title":"Immunopathogenic mechanisms and immunoregulatory therapies in MASLD","volume":"22","author":"He","year":"2025","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10.1016\/j.metabol.2026.156767_bb0275","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.metabol.2026.156767_bb0280","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4103\/ijem.ijem_528_24","article-title":"Fenofibrate in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis","volume":"29","author":"Kumar","year":"2025","journal-title":"Indian J Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.metabol.2026.156767_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-088862","article-title":"Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol","volume":"14","author":"Iwaki","year":"2024","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.metabol.2026.156767_bb0290","article-title":"Functional and structural insights into the human PPAR\u03b1\/\u03b4\/\u03b3 targeting preferences of anti-NASH investigational drugs, Lanifibranor, Seladelpar, and Elafibranor","volume":"12","author":"Kamata","year":"2023","journal-title":"Antioxidants (Basel)"},{"issue":"5","key":"10.1016\/j.metabol.2026.156767_bb0295","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s13300-025-01724-9","article-title":"Comparing efficacy of chiglitazar, pioglitazone, and semaglutide in type 2 diabetes: a retrospective study","volume":"16","author":"Li","year":"2025","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.metabol.2026.156767_bb0300","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2016.01.011","article-title":"Effects of combined PPAR-\u03b3 and PPAR-\u03b1 agonist therapy on fructose induced NASH in rats: modulation of gene expression","volume":"773","author":"Abd El-Haleim","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.metabol.2026.156767_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.119432","article-title":"Combination therapy with clinically approved PPAR\u03b1\/\u03b4\/\u03b3 subtype-selective agonists pemafibrate, seladelpar, and pioglitazone in a 4-week diet-induced early-stage MASLD mouse model","volume":"199","author":"Honda","year":"2026","journal-title":"Biomed Pharmacother"},{"issue":"14","key":"10.1016\/j.metabol.2026.156767_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21145093","article-title":"Combination of peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonists prevents corneal inflammation and neovascularization in a rat alkali burn model","volume":"21","author":"Nakano","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2026.156767_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117679","article-title":"The impact of single and combined PPAR-\u03b1 and PPAR-\u03b3 activation on the neurological outcomes following cerebral ischemia reperfusion","volume":"252","author":"Shehata","year":"2020","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.metabol.2026.156767_bb0320","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MPG.0000000000003796","article-title":"An open label, randomized, multicenter study of elafibranor in children with nonalcoholic steatohepatitis","volume":"77","author":"Goyal","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.metabol.2026.156767_bb0325","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70144","article-title":"Effectiveness of saroglitazar in MASLD patients: a prospective, real-world assessment of liver and metabolic health","volume":"9","author":"Gupta","year":"2026","journal-title":"Endocrinol Diabetes Metab"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0330","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jhep.2025.03.003","article-title":"Metabolic effects and mechanism of action of the pan-PPAR agonist lanifibranor","volume":"82","author":"Sabatini","year":"2025","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0335","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1021\/acs.jmedchem.7b01285","article-title":"Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) \u03b1\/\u03b3\/\u03b4 triple activators: discovery of lanifibranor, a new antifibrotic clinical candidate","volume":"61","author":"Boubia","year":"2018","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0340","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatol Commun"},{"issue":"12","key":"10.1016\/j.metabol.2026.156767_bb0345","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","article-title":"Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis","volume":"75","author":"Ruzehaji","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.metabol.2026.156767_bb0350","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1136\/annrheumdis-2016-210821","article-title":"Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension","volume":"76","author":"Avouac","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.metabol.2026.156767_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121817","article-title":"Modelling fatty liver disease with mouse liver-derived multicellular spheroids","volume":"290","author":"Van Os","year":"2022","journal-title":"Biomaterials"},{"issue":"30","key":"10.1016\/j.metabol.2026.156767_bb0360","article-title":"Dissecting acute drug-induced hepatotoxicity and therapeutic responses of steatotic liver disease using primary mouse liver and blood cells in a liver-on-A-chip model","volume":"11","author":"Liu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"15\u201316","key":"10.1016\/j.metabol.2026.156767_bb0365","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/scd.2024.0067","article-title":"Mice hepatic organoids for modeling nonalcoholic fatty liver disease and drug response","volume":"33","author":"Zhou","year":"2024","journal-title":"Stem Cells Dev"},{"issue":"1","key":"10.1016\/j.metabol.2026.156767_bb0370","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.1038\/s41598-024-58989-6","article-title":"Development of a high throughput system to screen compounds that revert the activated hepatic stellate cells to a quiescent-like state","volume":"14","author":"Nakano","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.metabol.2026.156767_bb0375","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages(\u2606)","volume":"73","author":"Lefere","year":"2020","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.metabol.2026.156767_bb0380","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/cts.13235","article-title":"Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH","volume":"15","author":"Mollerhoj","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.metabol.2026.156767_bb0385","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease","volume":"74","author":"Boyer-Diaz","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2026.156767_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117826","article-title":"The pan-PPAR agonist lanifibranor reduces portal pressure independent of fibrosis reduction through the splanchnic vasculature","volume":"183","author":"Heldens","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.metabol.2026.156767_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177945","article-title":"Lanifibranor and semaglutide demonstrate multiple metabolic benefits in free-choice diet induced obese hamster models of MASH and MetALD","volume":"1003","author":"Briand","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.metabol.2026.156767_bb0400","article-title":"A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study","volume":"98","author":"F","year":"2020","journal-title":"Contemp Clin Trials"},{"issue":"17","key":"10.1016\/j.metabol.2026.156767_bb0405","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.metabol.2026.156767_bb0410","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1016\/j.cgh.2024.12.039","article-title":"Biomarkers of histological response in lanifibranor-treated patients with metabolic dysfunction-associated steatohepatitis","volume":"23","author":"Boursier","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0415","article-title":"Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment","volume":"7","author":"Rautou","year":"2025","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0420","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2024.12.045","article-title":"Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD","volume":"82","author":"Barb","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2026.156767_bb0425","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.metabol.2026.156767_bb0430","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40265-021-01648-1","article-title":"Chiglitazar: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.metabol.2026.156767_bb0435","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1097\/HEP.0000000000001475","article-title":"Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: a phase II, randomized, double-blind, placebo-controlled study","volume":"83","author":"Sun","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2026.156767_bb0440","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/546548","article-title":"In vitro and in vivo characterizations of Chiglitazar, a newly identified PPAR pan-agonist","volume":"2012","author":"He","year":"2012","journal-title":"PPAR Res"},{"key":"10.1016\/j.metabol.2026.156767_bb0445","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5314187","article-title":"To probe full and partial activation of human peroxisome proliferator-activated receptors by pan-agonist Chiglitazar using molecular dynamics simulations","volume":"2020","author":"Sullivan H","year":"2020","journal-title":"PPAR Res"},{"issue":"5","key":"10.1016\/j.metabol.2026.156767_bb0450","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/sj.bjp.0706745","article-title":"The PPARalpha\/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats","volume":"148","author":"Li","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.metabol.2026.156767_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2024.112337","article-title":"Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice","volume":"593","author":"Liu","year":"2024","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0460","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40261-019-00779-4","article-title":"Pharmacokinetics, safety and tolerability of Chiglitazar, a novel peroxisome proliferator-activated receptor (PPAR) Pan-agonist, in healthy Chinese volunteers: a phase I study","volume":"39","author":"Xu","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"7","key":"10.1016\/j.metabol.2026.156767_bb0465","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/cpdd.893","article-title":"Pharmacokinetics and safety of chiglitazar, a peroxisome proliferator-activated receptor pan-agonist, in patients < 65 and \u2265 65 years with type 2 diabetes","volume":"10","author":"Li","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"10.1016\/j.metabol.2026.156767_bb0470","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cpdd.668","article-title":"Study on drug-drug interactions between chiglitazar, a novel PPAR Pan-agonist, and metformin hydrochloride in healthy subjects","volume":"8","author":"Yi","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"11","key":"10.1016\/j.metabol.2026.156767_bb0475","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1111\/dom.70009","article-title":"Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study)","volume":"27","author":"Gao","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"10.1016\/j.metabol.2026.156767_bb0480","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.scib.2021.03.019","article-title":"Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)","volume":"66","author":"Ji","year":"2021","journal-title":"Sci Bull (Beijing)"},{"issue":"15","key":"10.1016\/j.metabol.2026.156767_bb0485","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.scib.2021.02.027","article-title":"Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)","volume":"66","author":"Jia","year":"2021","journal-title":"Sci Bull (Beijing)"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0490","first-page":"1119","article-title":"Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment","volume":"17","author":"Hamada","year":"2000","journal-title":"Int J Oncol"},{"issue":"5","key":"10.1016\/j.metabol.2026.156767_bb0495","first-page":"1473","article-title":"Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate","volume":"10","author":"Ogawa","year":"2003","journal-title":"Oncol Rep"},{"issue":"10","key":"10.1016\/j.metabol.2026.156767_bb0500","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/j.1872-034X.2008.00363.x","article-title":"Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line","volume":"38","author":"Nakano","year":"2008","journal-title":"Hepatol Res"},{"key":"10.1016\/j.metabol.2026.156767_bb0505","doi-asserted-by":"crossref","DOI":"10.1186\/1476-511X-12-41","article-title":"Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease\u2014a historical prospective","volume":"12","author":"Schmilovitz-Weiss","year":"2013","journal-title":"Lipids Health Dis"},{"issue":"3","key":"10.1016\/j.metabol.2026.156767_bb0510","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.molmet.2016.12.007","article-title":"Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice","volume":"6","author":"Franko","year":"2017","journal-title":"Mol Metab"},{"issue":"9","key":"10.1016\/j.metabol.2026.156767_bb0515","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094726","article-title":"Functional and structural insights into human PPAR\u03b1\/\u03b4\/\u03b3 subtype selectivity of bezafibrate, fenofibric acid, and pemafibrate","volume":"23","author":"Honda","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1\u20133","key":"10.1016\/j.metabol.2026.156767_bb0520","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1388-1981(03)00065-9","article-title":"Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice","volume":"1632","author":"Peters","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2026.156767_bb0525","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1475-2840-11-140","article-title":"Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?","volume":"11","author":"Tenenbaum","year":"2012","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0530","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00125-016-3912-9","article-title":"Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-\u03b3 and PPAR-\u03b1 agonists on carbohydrate and lipid metabolism in db\/db and diet-induced obese mice","volume":"59","author":"Feng","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156767_bb0535","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jare.2023.02.007","article-title":"Bavachinin protects the liver in NAFLD by promoting regeneration via targeting PCNA","volume":"55","author":"Dong","year":"2024","journal-title":"J Adv Res"},{"issue":"10","key":"10.1016\/j.metabol.2026.156767_bb0540","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1002\/ptr.7912","article-title":"Bavachinin selectively modulates PPAR gamma and maintains bone homeostasis in type 2 diabetes","volume":"37","author":"Liu","year":"2023","journal-title":"Phytother Res"},{"issue":"Pt 2","key":"10.1016\/j.metabol.2026.156767_bb0545","article-title":"Research progress on pharmacological effects against liver and eye diseases of flavonoids present in Chrysanthum indicum L., Chrysanthemum morifolium Ramat., Buddleja officinalis maxim. and Sophora japonica L","volume":"338","author":"Xiong","year":"2025","journal-title":"J Ethnopharmacol"},{"issue":"8","key":"10.1016\/j.metabol.2026.156767_bb0550","article-title":"Hypolipidemic effects and preliminary mechanism of chrysanthemum flavonoids, its main components luteolin and luteoloside in hyperlipidemia rats","volume":"10","author":"Sun","year":"2021","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"10.1016\/j.metabol.2026.156767_bb0555","doi-asserted-by":"crossref","first-page":"40069","DOI":"10.1038\/s41598-025-25981-7","article-title":"Chrysanthemum morifolium extract improves metabolic dysfunction-associated fatty liver disease by regulating lipid metabolism","volume":"15","author":"Yu","year":"2025","journal-title":"Sci Rep"},{"issue":"Pt A","key":"10.1016\/j.metabol.2026.156767_bb0560","article-title":"Chrysanthemum morifolium Ramat. Water extract prevents and treats metabolic-associated fatty liver disease via pan-PPAR activity","volume":"355","author":"Zhu","year":"2026","journal-title":"J Ethnopharmacol"},{"issue":"5","key":"10.1016\/j.metabol.2026.156767_bb0565","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1046\/j.1523-1747.2001.01329.x","article-title":"Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid","volume":"116","author":"Westergaard","year":"2001","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.metabol.2026.156767_bb0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229322","article-title":"The PPAR pan-agonist tetradecylthioacetic acid promotes redistribution of plasma cholesterol towards large HDL","volume":"15","author":"Lund\u00e5sen","year":"2020","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.metabol.2026.156767_bb0575","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.livres.2024.09.001","article-title":"Meldonium-induced steatosis is associated with increased delta 6 desaturation and reduced elongation of n-6 polyunsaturated fatty acids","volume":"8","author":"Bj\u00f8rndal","year":"2024","journal-title":"Liver Res"},{"issue":"4","key":"10.1016\/j.metabol.2026.156767_bb0580","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1463-1326.2008.00958.x","article-title":"Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha\/delta activation and increased mitochondrial fatty acid oxidation","volume":"11","author":"L\u00f8v\u00e5s","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2026.156767_bb0585","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7196535","article-title":"Polydatin inhibits adipose tissue inflammation and ameliorates lipid metabolism in high-fat-fed mice","volume":"2019","author":"Zheng","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.metabol.2026.156767_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121766","article-title":"Polydatin ameliorates inflammation and oxidative stress associated with MSU-induced gouty arthritis in mice by regulating PPAR-\u03b3 and ferritin activation","volume":"326","author":"Du","year":"2023","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.metabol.2026.156767_bb0595","doi-asserted-by":"crossref","first-page":"26995","DOI":"10.1038\/s41598-025-12357-0","article-title":"In silico and in vitro investigations reveal pan-PPAR agonist activity and anti-NAFLD efficacy of polydatin by modulating hepatic lipid-energy metabolism","volume":"15","author":"Mandal","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.metabol.2026.156767_bb0600","doi-asserted-by":"crossref","first-page":"20221009","DOI":"10.1515\/biol-2022-1009","article-title":"Polydatin prevents cholesterol gallstone formation by regulating cholesterol metabolism via PPAR-\u03b3 signaling","volume":"20","author":"Li","year":"2025","journal-title":"Open Life Sci"},{"issue":"1","key":"10.1016\/j.metabol.2026.156767_bb0605","doi-asserted-by":"crossref","first-page":"9299","DOI":"10.1038\/s41598-022-13292-0","article-title":"Sustainable multifunctional phenolic lipids as potential therapeutics in dentistry","volume":"12","author":"Dame-Teixeira","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.metabol.2026.156767_bb0610","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1021\/acs.jmedchem.1c01542","article-title":"Phenolic lipids derived from cashew nut Shell liquid to treat metabolic diseases","volume":"65","author":"Sahin","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.metabol.2026.156767_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101958","article-title":"A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease","volume":"85","author":"Sahin","year":"2024","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2026.156767_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2024.112380","article-title":"LDT409 (pan-PPAR partial agonist) mitigates metabolic dysfunction-associated steatotic liver disease in high-fructose-fed mice","volume":"594","author":"Fernandes-Da-Silva","year":"2024","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.metabol.2026.156767_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116220","article-title":"A pan-PPAR agonist E17241 ameliorates hyperglycemia and diabetic dyslipidemia in KKAy mice via up-regulating ABCA1 in islet, liver, and white adipose tissue","volume":"172","author":"Sheng","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0630","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.120.314156","article-title":"E17241 as a novel ABCA1 (ATP-binding cassette transporter A1) upregulator ameliorates atherosclerosis in mice","volume":"41","author":"Xu","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.metabol.2026.156767_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.molpha.2025.100065","article-title":"The peroxisome proliferator-activated receptor \u03b1\/\u03b2\/\u03b3 agonist NCPC-626 from microbial metabolites alleviates metabolic dysfunction-associated steatohepatitis in mice","volume":"107","author":"Yu","year":"2025","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.metabol.2026.156767_bb0640","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.cmet.2014.06.010","article-title":"The PPAR\u03b1-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway","volume":"20","author":"Vernia","year":"2014","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.metabol.2026.156767_bb0645","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000370254","article-title":"PPAR\u03b3 agonist-induced fluid retention depends on \u03b1ENaC expression in connecting tubules","volume":"129","author":"Fu","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.metabol.2026.156767_bb0650","article-title":"The context-dependent roles of PPAR-\u03b3 in adipocyte differentiation and obesity: a master regulator with dual functions","volume":"13-2026","author":"Hou","year":"2026","journal-title":"Front Nutr"},{"key":"10.1016\/j.metabol.2026.156767_bb0655","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biochi.2013.11.011","article-title":"Peroxisome proliferator-activated receptor-\u03b1 activation and excess energy burning in hepatocarcinogenesis","volume":"98","author":"Misra","year":"2014","journal-title":"Biochimie"},{"issue":"5","key":"10.1016\/j.metabol.2026.156767_bb0660","doi-asserted-by":"crossref","DOI":"10.3390\/cells15050464","article-title":"Peroxisome proliferator-activated receptor beta\/delta: a link between metabolism, inflammation, and fibrosis in metabolic dysfunction-associated steatotic liver disease","volume":"15","author":"Palomer","year":"2026","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.metabol.2026.156767_bb0665","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000747","article-title":"Semaglutide versus other GLP-1 receptor agonists in patients with MASLD","volume":"9","author":"Kuo","year":"2025","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.metabol.2026.156767_bb0670","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70003","article-title":"Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: a systematic review","volume":"55","author":"Konings","year":"2025","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.metabol.2026.156767_bb0675","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.metabol.2026.156767_bb0680","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","article-title":"Thyroid hormone receptor-\u03b2 analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"82","author":"Ratziu","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2026.156767_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156043","article-title":"Comparative efficacy of THR-\u03b2 agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: a systematic review and network meta-analysis","volume":"161","author":"Lin","year":"2024","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.metabol.2026.156767_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108195","article-title":"Personalized glucose-lowering effect of chiglitazar in type 2 diabetes","volume":"26","author":"Huang","year":"2023","journal-title":"iScience"},{"issue":"4","key":"10.1016\/j.metabol.2026.156767_bb0695","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1248\/bpb.b12-00868","article-title":"The effect of sex hormones on peroxisome proliferator-activated receptor gamma expression and activity in mature adipocytes","volume":"36","author":"Sato","year":"2013","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"10.1016\/j.metabol.2026.156767_bb0700","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1124\/dmd.109.031542","article-title":"Human liver expression of CYP2C8: gender, age, and genotype effects","volume":"38","author":"Naraharisetti","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.metabol.2026.156767_bb0705","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/XCE.0000000000000057","article-title":"Relevance of low testosterone to non-alcoholic fatty liver disease","volume":"4","author":"Mody","year":"2015","journal-title":"Cardiovasc Endocrinol"},{"key":"10.1016\/j.metabol.2026.156767_bb0710","article-title":"Sex- and hepatocyte PPAR(gamma)-dependent effects of an obesogenic dietary approach to induce MASH with fibrosis in mice","author":"Sierra-Cruz","year":"2026","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/j.metabol.2026.156767_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101680","article-title":"The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study","volume":"51","author":"Tan","year":"2025","journal-title":"Diabetes Metab"},{"issue":"8","key":"10.1016\/j.metabol.2026.156767_bb0720","doi-asserted-by":"crossref","DOI":"10.3390\/biom13081264","article-title":"Current clinical trial status and future prospects of PPAR-targeted drugs for treating nonalcoholic fatty liver disease","volume":"13","author":"Kamata","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.metabol.2026.156767_bb0725","doi-asserted-by":"crossref","DOI":"10.1186\/1758-5996-6-83","article-title":"CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models","volume":"6","author":"Sadasivuni M","year":"2014","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.metabol.2026.156767_bb0730","doi-asserted-by":"crossref","DOI":"10.1155\/2007\/97125","article-title":"The effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan agonists on body weight, body mass, and serum lipid profiles in diet-induced obese AKR\/J mice","volume":"2007","author":"Harrington","year":"2007","journal-title":"PPAR Res"},{"key":"10.1016\/j.metabol.2026.156767_bb0735","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.freeradbiomed.2015.11.033","article-title":"PPAR-pan activation induces hepatic oxidative stress and lipidomic remodelling","volume":"95","author":"Ament","year":"2016","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.metabol.2026.156767_bb0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117533","article-title":"Design, synthesis, and biological evaluation of deuterated indolepropionic acid derivatives as novel long-acting pan PPAR\u03b1\/\u03b3\/\u03b4 agonists","volume":"96","author":"Chen","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.metabol.2026.156767_bb0745","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jconrel.2015.04.033","article-title":"Improved nonclinical pharmacokinetics and biodistribution of a new PPAR pan-agonist and COX inhibitor in nanocapsule formulation","volume":"209","author":"Garcia G","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.metabol.2026.156767_bb0750","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.vph.2015.03.009","article-title":"New indole-thiazolidine attenuates atherosclerosis in LDLr(\u2212\/\u2212) mice","volume":"71","author":"C\u00e9sar F","year":"2015","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.metabol.2026.156767_bb0755","article-title":"Polydatin, a glycoside of resveratrol, is better than resveratrol in alleviating non-alcoholic fatty liver disease in mice fed a high-fructose diet","volume":"9","author":"Zhao","year":"2022","journal-title":"Front Nutr"},{"issue":"4","key":"10.1016\/j.metabol.2026.156767_bb0760","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096056","article-title":"Novel PPAR pan agonist, ZBH ameliorates hyperlipidemia and insulin resistance in high fat diet induced hyperlipidemic hamster","volume":"9","author":"Chen","year":"2014","journal-title":"PloS One"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526002805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526002805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:38:39Z","timestamp":1791520719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049526002805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":152,"alternative-id":["S0026049526002805"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156767","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pan-PPAR agonists: Emerging therapeutic strategies for metabolic dysfunction-associated steatotic liver disease","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156767","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156767"}}